PET Imaging with Prostate-Specific Membrane Antigen for Prostate Cancer: Clinical Utility


( Last Updated : November 26, 2020)
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1527-000

Details


Question


  1. What is the clinical utility of positron emission tomography (PET) imaging using prostate-specific membrane antigen (PSMA) labelled with gallium-68 (Ga-68) or fluorine-18 (F-18) in patients with suspected or confirmed metastatic or biochemically recurrent prostate cancer?


Key Message

Four systematic reviews (one with a meta-analysis), one randomized controlled trial, and 30 non-randomized studies were identified regarding the clinical utility of positron emission tomography imaging using prostate-specific membrane antigen labelled with gallium-68 or fluorine-18 in patients with suspected or confirmed metastatic or biochemically recurrent prostate cancer.